And Still They Come Over Troubled Waters: Can Asia's Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC.

Subjects

Subjects :

Acrylamides
Asia
ErbB Receptors genetics
Humans
Indoles
Morpholines
Mutation
Protein Kinase Inhibitors pharmacology
Protein Kinase Inhibitors therapeutic use
Pyrazoles
Pyrimidines
Carcinoma, Non-Small-Cell Lung drug therapy
Lung Neoplasms drug therapy

Details

Language :

English

ISSN :

1556-1380

Volume :

17

Issue :

10

Database :

MEDLINE

Journal :

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Publication Type :

Editorial & Opinion

Accession number :

36192074

Full Text :

https://doi.org/10.1016/j.jtho.2022.08.016